Literature DB >> 8359068

Terminal ileal mucosal mast cells in irritable bowel syndrome.

A P Weston1, W L Biddle, P S Bhatia, P B Miner.   

Abstract

Terminal ileal biopsies were prospectively obtained and stained specifically for mast cells in 20 patients with irritable bowel syndrome (IBS) and 15 controls. The number of terminal ileal mast cells per high powered field (MC/HPF) (mean +/- SEM) was 23.3 +/- 3.1 for IBS and 6.8 +/- 1.1 for controls (P = 0.0001). The diarrhea IBS subgroup had the greatest number of MC/HPF. No correlation was found between terminal ileal mucosal mast cell counts (MMCC) and the number of Manning criteria present or the functional bowel disease score (r = 0.06 and r = -0.31, respectively). We conclude that terminal ileal MMCC are significantly elevated in a majority of patients with IBS. The mast cell may be responsible for the altered visceral perception found in the gastrointestinal tract in patients with IBS. The poor correlation of the MMCC to the clinical features of IBS may be the result of the dynamic state of the mast cell.

Entities:  

Mesh:

Year:  1993        PMID: 8359068     DOI: 10.1007/bf01303164

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  AMITRIPTYLINE IN THE TREATMENT OF GASTROINTESTINAL DISORDERS.

Authors:  S DIAMOND
Journal:  Psychosomatics       Date:  1964 Jul-Aug       Impact factor: 2.386

2.  The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases.

Authors:  N A CHAUDHARY; S C TRUELOVE
Journal:  Q J Med       Date:  1962-07

Review 3.  Bladder mast cell activation in interstitial cystitis.

Authors:  T C Theoharides; G R Sant
Journal:  Semin Urol       Date:  1991-05

4.  Differential release of serotonin and histamine from mast cells.

Authors:  T C Theoharides; P K Bondy; N D Tsakalos; P W Askenase
Journal:  Nature       Date:  1982-05-20       Impact factor: 49.962

5.  A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea.

Authors:  E Oddsson; J Rask-Madsen; E Krag
Journal:  Scand J Gastroenterol       Date:  1978       Impact factor: 2.423

6.  A patient questionnaire to identify bowel disease.

Authors:  N J Talley; S F Phillips; J Melton; C Wiltgen; A R Zinsmeister
Journal:  Ann Intern Med       Date:  1989-10-15       Impact factor: 25.391

7.  Immunologically mediated intestinal mastocytosis in Nippostrongylus brasiliensis-infected rats.

Authors:  A D Befus; J Bienenstock
Journal:  Immunology       Date:  1979-09       Impact factor: 7.397

8.  Histamine action on guinea pig ileal mucosa.

Authors:  H J Cooke; P R Nemeth; J D Wood
Journal:  Am J Physiol       Date:  1984-04

9.  Towards positive diagnosis of the irritable bowel.

Authors:  A P Manning; W G Thompson; K W Heaton; A F Morris
Journal:  Br Med J       Date:  1978-09-02

10.  Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome.

Authors:  A Prior; N W Read
Journal:  Aliment Pharmacol Ther       Date:  1993-04       Impact factor: 8.171

View more
  85 in total

1.  The putative role of inflammation in the irritable bowel syndrome.

Authors:  S M Collins; T Piche; P Rampal
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

2.  East meets West: infection, nerves, and mast cells in the irritable bowel syndrome.

Authors:  S M Collins; G Barbara
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 3.  Putative therapeutic targets in the treatment of visceral hyperalgesia.

Authors:  S Collins
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

4.  Probiotic treatment induced change of inflammation related metabolites in IBS-D patients/double-blind, randomized, placebo-controlled trial.

Authors:  Jinjoo Kim; Kumsun Cho; Joo Sung Kim; Hyun Chae Jung; Bumsik Kim; Myeong Soo Park; Geun Eog Ji; Joo-Youn Cho; Kyoung Sup Hong
Journal:  Food Sci Biotechnol       Date:  2019-12-23       Impact factor: 2.391

5.  HLA-DQ genotype is associated with accelerated small bowel transit in patients with diarrhea-predominant irritable bowel syndrome.

Authors:  Maria I Vazquez-Roque; Michael Camilleri; Paula Carlson; Sanna McKinzie; Joseph A Murray; Tricia L Brantner; Duane D Burton; Alan R Zinsmeister
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-06       Impact factor: 2.566

6.  Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis.

Authors:  Ji Yong Ahn; Kyung Hun Lee; Chang Hwan Choi; Ju Wan Kim; Hyun Woong Lee; Jeong Wook Kim; Mi Kyung Kim; Gui Young Kwon; Seungbong Han; Seong-Eun Kim; Sung Min Kim; Sae Kyung Chang
Journal:  Dig Dis Sci       Date:  2013-11-27       Impact factor: 3.199

Review 7.  Interstitial cystitis/bladder pain syndrome: The evolving landscape, animal models and future perspectives.

Authors:  Yoshiyuki Akiyama; Yi Luo; Philip M Hanno; Daichi Maeda; Yukio Homma
Journal:  Int J Urol       Date:  2020-04-04       Impact factor: 3.369

8.  Subjects with diarrhea-predominant IBS have increased rectal permeability responsive to tryptase.

Authors:  Jae Woong Lee; Jung Ho Park; Dong I L Park; Jung-Hwan Park; Hong Joo Kim; Yong Kyun Cho; Chong I L Sohn; Woo Kyu Jeon; Byung Ik Kim
Journal:  Dig Dis Sci       Date:  2010-01-20       Impact factor: 3.199

9.  Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome.

Authors:  Olafur S Palsson; Olivier Morteau; Eugene M Bozymski; John T Woosley; R Balfour Sartor; Michael J Davies; David A Johnson; Marsha J Turner; William E Whitehead
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

10.  Food Intolerance: Dietary Treatments in Functional Bowel Disorders.

Authors:  Maria O'Sullivan; Colm O'Morain
Journal:  Curr Treat Options Gastroenterol       Date:  2003-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.